G1 Therapeutics Stock Target Price
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
G1 Therapeutics fundamentals help investors to digest information that contributes to G1 Therapeutics' financial success or failures. It also enables traders to predict the movement of GTHX Stock. The fundamental analysis module provides a way to measure G1 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to G1 Therapeutics stock.
GTHX |
GTHX Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses G1 Therapeutics' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of G1 Therapeutics could also be used in its relative valuation, which is a method of valuing G1 Therapeutics by comparing valuation metrics of similar companies.G1 Therapeutics is currently under evaluation in target price category among its peers.
GTHX Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Shares Owned By Insiders | 10.92 % | |||
| Shares Owned By Institutions | 54.61 % | |||
| Number Of Shares Shorted | 3.41 M | |||
| Price To Earning | (1.95) X | |||
| Price To Book | 15.34 X | |||
| Price To Sales | 6.48 X | |||
| Revenue | 82.51 M | |||
| Gross Profit | 47.55 M | |||
| EBITDA | (39.01 M) | |||
| Net Income | (47.97 M) | |||
| Cash And Equivalents | 143.96 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 57.17 M | |||
| Debt To Equity | 1.24 % | |||
| Current Ratio | 4.75 X | |||
| Book Value Per Share | 0.47 X | |||
| Cash Flow From Operations | (38.34 M) | |||
| Short Ratio | 1.01 X | |||
| Earnings Per Share | (0.86) X | |||
| Target Price | 7.15 | |||
| Number Of Employees | 100 | |||
| Beta | 1.68 | |||
| Market Capitalization | 377.22 M | |||
| Total Asset | 121.54 M | |||
| Retained Earnings | (779.99 M) | |||
| Working Capital | 85.23 M | |||
| Current Asset | 252.33 M | |||
| Current Liabilities | 9.86 M | |||
| Net Asset | 121.54 M |
About G1 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze G1 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of G1 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of G1 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |